Aquestive Therapeutics Inc (AQST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) has a cash flow conversion efficiency ratio of 0.435x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.81 Million) by net assets ($-34.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Aquestive Therapeutics Inc (AQST) balance sheet quality index to measure how much of total assets are equity-financed.
Aquestive Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Aquestive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Aquestive Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Aquestive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aquestive Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Anup Engineering Limited
NSE:ANUP
|
-0.098x |
|
GuangDong Topstrong Living Innovation & Integration Co Ltd Class A
SHE:300749
|
0.057x |
|
Haixia Envrnmnt
SHG:603817
|
0.015x |
|
Temple & Webster Group Ltd
AU:TPW
|
0.227x |
|
Shanghai Shine-Link Intl
SHG:603648
|
0.085x |
|
Hangzhou CNCR-IT Co Ltd
SHE:300250
|
0.018x |
|
Zinzino AB Series B
ST:ZZ-B
|
0.384x |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
0.019x |
Annual Cash Flow Conversion Efficiency for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Aquestive Therapeutics Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Aquestive Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-33.66 Million | $-52.43 Million | 1.558x | +162.03% |
| 2024-12-31 | $-60.16 Million | $-35.76 Million | 0.594x | +892.16% |
| 2023-12-31 | $-106.49 Million | $-6.38 Million | 0.060x | -27.44% |
| 2022-12-31 | $-118.55 Million | $-9.79 Million | 0.083x | -79.44% |
| 2021-12-31 | $-82.13 Million | $-32.98 Million | 0.402x | -57.16% |
| 2020-12-31 | $-48.50 Million | $-45.46 Million | 0.937x | -90.47% |
| 2019-12-31 | $-6.12 Million | $-60.21 Million | 9.835x | +863.12% |
| 2018-12-31 | $10.08 Million | $-12.99 Million | -1.289x | -486.31% |
| 2017-12-31 | $-26.50 Million | $5.82 Million | -0.220x | -147.26% |
| 2016-12-31 | $-17.58 Million | $-8.18 Million | 0.465x | +226.96% |
| 2006-12-31 | $25.26 Million | $-9.26 Million | -0.366x | +73.28% |
| 2005-12-31 | $4.67 Million | $-6.39 Million | -1.371x | -- |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more